Loss of tumor suppressor ARID1A protein expression correlates with poor prognosis in patients with primary breast cancer

Journal of Breast Cancer

Volumn 18, Issue 4, 2015, Pages 339-346

  Cho, Hyun Deuk ^a   Lee, Jong Eun ^a   Jung, Hae Yoen ^a   Oh, Mee Hye ^a   Lee, Ji Hye ^a   Jang, Si Hyong ^a   Kim, Kyung Ju ^a   Han, Sun Wook ^a   Kim, Sung Yong ^a   Kim, Han Jo ^a   Bae, Sang Byung ^a   Lee, Hyun Ju ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

ARID1A protein; Breast neoplasms; Immunohistochemistry; Prognosis

Indexed keywords

ADULT; ARID1A GENE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; DISEASE FREE INTERVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; SOMATIC MUTATION; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

EID: 84957612755     PISSN: 17386756     EISSN: 20929900     Source Type: Journal    
DOI: 10.4048/jbc.2015.18.4.339     Document Type: Article

References (29)

1. Yoon JH, Kim MJ, Kim EK, Moon HJ. Imaging surveillance of patients with breast cancer after primary treatment: current recommendations. Korean J Radiol 2015;16:219-28.
2. Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 2012;31:2090-100.
3. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012;33:100-3.
4. Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov 2013;3:35-43.
5. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-92.
6. Itamochi H, Oumi N, Oishi T, Shoji T, Fujiwara H, Sugiyama T, et al. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. Int J Clin Oncol 2015;20:967-73.
7. Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 2013;26:1525-35.
8. Mao TL, Shih Ie M. The roles of ARID1A in gynecologic cancer. J Gynecol Oncol 2013;24:376-81.
9. Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH. Loss of ARID1A/ BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol 2013;44:1365-74.
10. Park JH, Lee C, Suh JH, Chae JY, Kim HW, Moon KC. Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma. Hum Pathol 2015;46:454-60.
11. Kim MJ, Gu MJ, Chang HK, Yu E. Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma. Histopathology 2015;66:508-16.
12. Rao Q, Xia QY, Wang ZY, Li L, Shen Q, Shi SS, et al. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Histopathology 2015;67:121-9.
13. Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, et al. ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Hum Pathol 2014;45:1258-68.
14. Zhang Y, Xu X, Zhang M, Bai X, Li H, Kan L, et al. ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosis. Tumour Biol 2014;35:5701-7.
15. Balbás-Martínez C, Rodríguez-Pinilla M, Casanova A, Domínguez O, Pisano DG, Gómez G, et al. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS One 2013;8:e62483.
16. Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T, Taketani Y, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010;11:5120-8.
17. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
18. Zhang X, Zhang Y, Yang Y, Niu M, Sun S, Ji H, et al. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol 2012;36:288-93.
19. Zhao J, Liu C, Zhao Z. ARID1A: a potential prognostic factor for breast cancer. Tumour Biol 2014;35:4813-9.
20. Lakhani SR EI, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. 4th ed. Lyon: International Agency for Research on Cancer; 2012.
21. Im S, Choi HJ, Yoo C, Jung JH, Jeon YW, Suh YJ, et al. Hedgehog related protein expression in breast cancer: gli-2 is associated with poor overall survival. Korean J Pathol 2013;47:116-23.
22. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
23. Guan B, Gao M, Wu CH, Wang TL, Shih IeM. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia 2012;14:986-93.
24. Cornen S, Adelaide J, Bertucci F, Finetti P, Guille A, Birnbaum DJ, et al. Mutations and deletions of ARID1A in breast tumors. Oncogene 2012; 31:4255-6.
25. Zhang X, Sun Q, Shan M, Niu M, Liu T, Xia B, et al. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers. PLoS One 2013;8:e53931.
26. Lee SY, Kim DW, Lee HS, Ihn MH, Oh HK, Park do J, et al. Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies. Oncology 2015;88:234-40.
27. Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011;71:6718-27.
28. Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW III, Khabele D, et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol 2013;26:1101-10.
29. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 2015;21:231-8.